SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis
16 references·1 citing·34 second hop
Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis (2020)Efficacy of psychedelic treatments on dep…Cochrane Handbook for Systematic Reviews of Interventions (2020)Cochrane Handbook for Systema…Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial (2018)Rapid antidepressant effects …Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression (2018)Quality of Acute Psychedelic …Psilocybin with psychological support for treatment-resistant depression: six-month follow-up (2017)Psilocybin with psychological…Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms (2017)Psilocybin for treatment-resi…Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial (2016)Rapid and sustained symptom r…Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study (2016)Psilocybin with psychological…Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial (2016)Psilocybin produces substanti…Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study (2015)Psilocybin-assisted treatment…Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases (2014)Safety and Efficacy of Lyserg…Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction (2014)Pilot study of the 5-HT 2A R …Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin (2012)Neural correlates of the psyc…Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer (2010)Pilot Study of Psilocybin Tre…The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration (2009)The PRISMA Statement for Repo…Measuring inconsistency in meta-analyses (2003)Measuring inconsistency in me…Evaluating non-randomised intervention studies (2003)Evaluating non-randomised int…Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis (2024)Efficacy of psilocybin for tr…Experimental and Quasi-Experimental Designs for Research (1963)Assessing the quality of reports of randomized clinical trials: Is blinding necessary? (1996)Meta-analysis of Observational Studies in Epidemiology A Proposal for Reporting (2000)Systematic reviews: CRD's guidance for undertaking reviews in health care (2010)GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias) (2011)Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement (2012)Hallucinogens (2004)Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance (2006)REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics (2019)The varieties of religious experience: A study in human nature. (1902)Universals in the Content and Structure of Values: Theoretical Advances and Empirical Tests in 20 Countries (1992)Combining effect size estimates in meta-analysis with repeated measures and independent-groups designs. (2002)Neural correlates of the LSD experience revealed by multimodal neuroimaging (2016)The Combination of Estimates from Different Experiments (1954)Funnel plots for detecting bias in meta-analysis (2001)Quantifying heterogeneity in a meta‐analysis (2002)The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration (2009)Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation (2015)An Inventory for Measuring Depression (1961)The Brief Psychiatric Rating Scale (1962)Diagnostic and Statistical Manual of Mental Disorders (2013)Psychedelics Promote Structural and Functional Neural Plasticity (2018)Manual for the State-Trait Anxiety Inventory (1970)The Hospital Anxiety and Depression Scale (1983)Optimism, coping, and health: Assessment and implications of generalized outcome expectancies. (1985)Psychedelics (2016)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (2009)Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement (2009)The PRISMA 2020 statement: an updated guideline for reporting systematic reviews (2021)Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder (2020)Trial of Psilocybin versus Escitalopram for Depression (2021)Positive psychology interventions: a meta-analysis of randomized controlled studies (2013)AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both (2017)Declaración PRISMA 2020: una guía actualizada para la publicación de revisiones sistemáticas (2021)
this work references cited by second hop

References

  • 2003Measuring inconsistency in meta-analyses63,086 cited
  • 2009The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration28,094 cited
  • 2020Cochrane Handbook for Systematic Reviews of Interventions5,670 cited
  • 2003Evaluating non-randomised intervention studies2,905 cited
  • 2016Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial2,196 cited
  • 2016Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial1,696 cited
  • 2016Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study1,533 cited
  • 2010Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer1,205 cited
  • 2012Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin1,170 cited
  • 2015Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study1,150 cited
  • 2017Psilocybin with psychological support for treatment-resistant depression: six-month follow-up969 cited
  • 2014Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction913 cited
  • 2018Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

851 cited
  • 2018Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression806 cited
  • 2014Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases749 cited
  • 2017Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms587 cited
  • Cited by

    • 2024Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis93 cited